HealthEdge, a healthcare focused private equity fund, completed the investment in Anodyne, a provider of lifestyle-oriented clinical footwear solutions most commonly prescribed for diabetic patients. Financial terms were not disclosed. "Diabetic foot complications represent a significant medical risk to the growing diabetic population. A risk that can be drastically mitigated by the proper application of therapeutic footwear. It is exciting to see how a relatively low-cost intervention can have such a meaningful impact on improved patient outcomes. We look forward to partnering with the Anodyne team to expand the reach of this important preventative product," Scott Heberlein, HealthEdge Partner.